Evidence map›Paper›PMID 42273186›Full record

ArticleJournal of asthma and allergy2026

Racial and Socioeconomic Differences in Real-World Use of Biologic Therapy for Asthma.

Monica Littlejohn, Autumn D Zuckerman, Nicolas Gargurevich, Leena Choi, Robert Lubwama, Richard H Stanford, Caresse Campbell, Manuel Nunez, Natalia Petruski-Ivleva, Anne-Laure Tardy and 1 more

Abstract read
In one paragraph

Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Monica LittlejohnVanderbilt Specialty Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0009-0001-7612-323X
Autumn D ZuckermanVanderbilt Specialty Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0002-8376-0691
Nicolas GargurevichDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Leena ChoiDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.
Robert LubwamaHealth Outcomes and Value Assessment (HEVA) Specialty Care, Sanofi, Bridgewater, NJ, USA.ORCID 0009-0001-5835-3373
Richard H StanfordStrategic Partnerships, AESARA, Inc, Chapel Hill, NC, USA.ORCID 0000-0001-5795-1147
Caresse CampbellMedical Value Evidence and Insight, Sanofi, Cambridge, MA, USA.
Manuel NunezNeurology Medical Affairs, Sanofi, Bridgewater, NJ, USA.
Natalia Petruski-IvlevaHealth Outcomes and Value Assessment (HEVA) Specialty Care, Sanofi, Cambridge, MA, USA.
Anne-Laure TardyHealth Outcomes and Value Assessment (HEVA) Specialty Care, Sanofi, Gentilly, France.
Katie CruchelowVanderbilt Specialty Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: Determine if there is a difference in race, socioeconomic factors and baseline asthma severity at the time of biologic initiation and whether those characteristics are associated with response to therapy within 18 months of initiation. Additionally, evaluate racial differences in clinic engagement, healthcare utilization, and biologic adherence. Patients and Methods: Retrospective review of patients initiating biologic therapy for moderate-severe asthma from January 1, 2019-June 30, 2022. Multiple linear regression analyses were performed to examine whether race and socioeconomic status were associated with race-neutral percent predicted forced expiratory volume in one second (ppFEV1) prior to biologic prescription and within 18 months post biologic initiation. Differences in clinic engagement and healthcare utilization by race were assessed using Wilcoxon rank sum tests. Adherence was calculated using proportion of days covered (PDC). Results: Patients (N=215) were White (69%) or Black or African American (27%). Most had commercial (54%) or Medicare (22%) insurance. At the time of biologic initiation, Black or African American/Other patients were estimated to have a 6.9% lower ppFEV1 than White patients ( Conclusion: Although not statistically significant, our findings suggest a possible trend where Black or African American/Other patients had lower ppFEV1 at the time of biologic initiation, indicating an opportunity for earlier interventions.

Indexed as

asthmahealth inequitiessocial determinants of healthsocial factors

Identifiers

PMID42273186
PMCPMC13248965

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.